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a b s t r a c t
Gorham–Stout disease is a rare disease characterized by anarchic lymphovascular proliferation causing
resorption of bone sometimes leading to disastrous complications. Bone tissue is progressively replaced
by angiomatic and lymphangiomatic tissue and ﬁnally by ﬁbrous tissue. This disease is known to be
ubiquitous and of complex etiology.
We present a case of Gorham–Stout disease of the proximal ﬁbula invading the proximal tibia and
soft tissues of the popliteal space that was successfully treated with radiotherapy and zoledronic acid.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Gorham–Stout Disease (GSD), also known as ‘massive osteolysis’
and ‘vanishing bone disease’, is a rare bone condition characterized
by spontaneous, idiopathic, and progressive proliferation of thin-
walled vascular and lymphatic vessels replacing bone and marrow
space by ﬁbrous connective tissue. It leads to bone destruction which
may sometimes be followed by new bone production [1]. In 1838
Jackson described the ﬁrst case of a patient with a “boneless arm” [2].
Clinical and anatomopathological features were described by Gorham
and Stout in 1955. They showed that this disease leads to progressive
massive osteolysis by invasion of bone by lymphangiomatic tissue
[3]. GSD mostly occurs in young adults; mean age is 25 years. Male
and female are equally affected, without inheritance pattern or race
predilection [4]. Clinical symptoms vary based on the location of
bone involvement. This disease is most often regional and may
involve several bones around a joint. Evolution may differ from one
patient to another, GSD can be benign with a tendency to self-
limitation or even spontaneous regression but it can also be very
disabling [3]. Known to be ubiquitous, it frequently affects the skull
and maxillofacial bones, ribs, cervical vertebrae, shoulder and pelvic
girdle bones [5,6]. The affected bone(s) weaken(s) progressively, and
pain and spontaneous fractures are the most common clinical
features besides swelling and progressive deformity of the affected
extremity. When localized at a lower extremity, limb length dis-
crepancy and axial deformation may lead to gait abnormalities and
major limping can occur [7]. Depending on location, it may also lead
to neurological complications and paralysis (in case of vertebrae
involvement), respiratory insufﬁciency and sometimes to death [8].
X-rays commonly show a typical licked candy stick appearance,
based on concentric bone resorption. Common blood tests are
usually normal, but bone alkaline phosphatase (BAP) may be
elevated if a fracture occurred [8]. GSD is a diagnosis of exclusion.
Diseases responsible of bone osteolysis such as infections, inﬂam-
matory or endocrine disorders, intraosseous malignancies or
metastases should be considered [1].
Radiographic and anatomopathological characteristics are used
as pathognomonic features for the diagnosis of GSD [1]. Treat-
ments include surgery, radiation and medical therapy. Surgery is
reserved for severe cases, e.g. when pathological fractures need to
be ﬁxed or when en bloc resection is required. Reconstruction is
achieved with bone grafts or alloplastic prostheses if instability
occurs. Interventions are often quite invasive. Recurrence rate is
close to 20% [1]. Radiotherapy is usually chosen in order to reverse
the progression of the lymphangiomatosis and to treat lesions that
are not surgically resectable, at least without major consequences.
Post-operative radiotherapy is required when the lesion could not
be resected in one piece [9]. There are no “Food and Drug
Administration” (FDA) approved therapies for the treatment of
GSD. Several drugs have nevertheless been tried, including bispho-
sphonates (etidronate, clodronate, pamidronate and zoledronic
acid) [10–14], interferon alpha-2b [14,15], anti-VEGF-A antibody,
bevacizumab, propranolol [16], low molecular weight heparin,
steroids, vitamin D and calcitonin [17,18]. However the experience
with these compounds, including bisphosphonates, is extremely
limited. We found only one report of a patient treated with
zoledronic acid [11]. On the opposite, the use of zoledronic acid,
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the most powerful bisphosphonate, has become an integral
component of cancer treatment in patients with metastatic bone
disease. The drugs markedly delay and decrease the occurrence of
skeletal-related events [19].
Etiology and mechanism of bone resorption in GSD remain
poorly understood [3,7,8,20]. In a recent review the potential role
of endothelial cells, macrophages, osteoclasts and osteoblasts is
discussed. Active lymphangiomatosis and haemangiomatosis may
be triggered by secretion of VEGF through activation of receptors of
lymphatic and blood endothelial cells. Patients presenting GSD have
high VEGF-A and -C blood levels whereas anti-lymphagiogenic
factors levels (VEGFR2, TGF-beta, IFN-gamma, etc.) are reported to
be low, maybe contributing to uncontrolled growth of lymphatic
vessels in the affected bones [21]. Osteoclastic activity may vary
according to the phase of the disease. On the one hand, osteoclast
differenciation is stimulated by macrophages, VEGF-A, -C, -D and IL-
6. On the other hand, high levels of TNF-alpha (produced by
macrophages) inhibit osteoblastogenesis and promote osteoclasto-
genesis. Inhibition of osteoprotegerin and enhanced production of
RANKL contribute to stimulate bone resorption. Bone homeostasis
appears to be unaffected in other parts of the skeleton [21–22].
Bone is in a constant state of remodeling. The functions of
osteoblasts and osteoclasts are well balanced to maintain bone
homeostasis [23]. Bone diseases such as bone metastases that alter
this equilibrium in favor of osteoclasts can induce loss of structural
integrity of the skeleton. In this situation osteoclasts resorb bone
by secreting proteases that dissolve the matrix and acids that
release bone mineral into the extracellular space. In GSD the
situation is more complex because of replacement of the bone
by a ﬁbrous tissue [23].
Nevertheless, considering the existence of a high osteoclastic
activity, use of combination of radiotherapy and bisphosponate has
been tried in a few patients. Bisphosphonates have been chosen
because of their anti-osteoclastic but also anti-angiogenic activ-
ities. Side effects of zoledronic acid are usually mild and, although
renal function has to be checked before each infusion, the risk of
osteonecrosis of the jaw is not negligible at high doses [23–24].
2. Case report
We report on a 28-year-old male without any past medical
history. After a minor work accident (professional mechanic) he
noticed signiﬁcant pain in his left knee. The pain increased over
time and a radiograph was taken. It showed minor bone resorption
at the neck of the left proximal ﬁbula (Fig. 1). The patient was
treated by minor pain medications. Despite 6 months of sympto-
matic care, pain did not resolve and limping appeared. Another X-
ray was taken that showed a concentric shrinkage of almost all
proximal ﬁbula, a typical “licked candy stick” appearance. This
image led to the radiological presumption of bone tumor. Bone
scan showed increased Technetium uptake in the left tibial plateau
extending to both the left tibial tuberosity and the left proximal
ﬁbula (Fig. 2). Computed-tomography scanner (CT-scan) showed
bone resorption in those areas. Around the tibial metaphysis there
was an area of massive osteolysis that looked like a pathological
fracture. Magnetic resonance imaging (MRI) emphasized involve-
ment of the left ﬁbula and tibia by exuberant disorganized vessels
also invading soft tissue of the popliteal space (Fig. 3). Biopsy was
taken and histology described a diffuse lymphangioma, showing
irregular vascular channels lined by a single epithelial layer, which
were embedded in a ﬁbrous stroma also containing residual bone
trabeculae (Fig. 4). Endothelial cells did not display any atypia.
They expressed podoplanin (D240), which conﬁrmed their lym-
phatic differentiation. Radiologic imaging combined with histo-
pathology conﬁrmed the diagnosis of Gorham–Stout disease.
Fig. 1. X-ray shows complete disappearance of the proximal part of ﬁbula and a
typical licked candy stick appearance.
Fig. 2. Bone scan – hypercaptation of the left proximal ﬁbula and tibial plateau.
Fig. 3. MRI shows lymphangiomatosis inﬁltrating left popliteal space, ﬁbula
and tibia.
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The patient was ﬁrst treated by radiotherapy with a total dose
of 40 Gy given in 2 Gy fractions, once a day for 20 days. Thereafter,
intravenous zoledronic acid (Zometas – 4 mg) was administered
once every 2 months during 24 months. The patient also received
adequate supplementation of vitamin D and calcium. No surgical
treatment was considered because of the low aggressive behavior
and the necessity for extensive surgery given the location.
We monitored the biological responses to zoledronic acid
through the measurement of bone alkaline phosphatase (BAP)
and C-terminal telopeptide (CTX), a speciﬁc marker of bone
resorption. Both markers rapidly decreased after initiation of
bisphosphonate therapy (Fig. 5). We also closely monitored serum
levels of calcium (Ca), creatinine, 25(OH)-vitamin D and parathyr-
oid hormone (PTH). There was no side effect of zoledronic acid
therapy and serum levels of creatinine, Ca and PTH remained
normal throughout therapy (data not shown).
At thirty months after the end of the medical treatment, the
patient’s situation improved markedly. Pain disappeared and was
only present after longstanding solicitation. MRI showed major
reduction of the bone invading lymphangioma (Fig. 6a). On
radiographs slight bone regeneration was observed and remaining
bone surfaces seemed stable (Fig. 6b, c).
3. Discussion
The invasion of the ﬁbula and part of the tibia is a rare
localization of GSD. Generally these lesions are found around the
skull and maxillofacial bones, shoulder and pelvic girdle bones but
quite rarely around the distal parts of the extremities [1]. In our
case report, trauma was considered by the patient as a trigger for
the development of GSD, but trauma has never been described as a
risk factor for its development [2,3].
Radiation therapy (RT) is suggested by many authors as the
most effective treatment of GSD [1,10,25]. Its role is to stop
endothelial cell proliferation and therefore avoid progression of
bone resorption. Dunbar et al. reported that treatment by radio-
therapy (dose ranging from 40 to 45 Gy) leads to a good clinical
outcome and few long-term complications. However, this study
only included 4 patients [9]. A German team reported 10 cases of
massive osteolysis treated by radiotherapy. Indications of RT alone
were surgically unresectable lesions [1]. Postoperative-RT may
also be given as an adjunct to surgery. Patients who were treated
with doses over 36 Gy had a tendency to disease stabilization and
less than 5% showed slight to moderate remineralization [1].
General outcomes were in favor of disease stabilization, allowing
to conclude that radiotherapy (doses ranging from 30 to 45 Gy)
might prevent osteolysis progression in up to 80% of cases [1]. In
our patient, despite radiotherapy at efﬁcient doses, bone resorp-
tion, estimated by serum CTX levels, was still elevated, arguing for
persistent tumor-induced osteolysis. Additional treatment with
the bisphosphonate zoledronic acid showed a rapid and persistent
suppression of CTX levels and a marked decrease in BAP levels
(Fig. 5). Such changes are similar to what is observed after
bisphosphonate therapy in patients with metastatic bone disease
[26,27]. For such patients, 4 mg of zoledronic acid is administered
every 4 weeks during at least 2 years [23]. In the absence of
guidelines, we chose to administer the classical dose of 4 mg of
zoledronic acid once every 2 months since the bone lesion was
unique. This reduced dosing should also be less likely to induce
side effects such as osteonecrosis of the jaw [28].
Fig. 4. Bone biopsy of left proximal part of ﬁbula, showing diffuse
lymphangiomatosis.
Fig. 5
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Along the same line, there is no information in the literature on
the optimal RT schedule in such cases. Doses ranging from 40 to
45 Gy should be adequate and we chose to give 2 Gy daily. This
schedule was based on clinical and radiological evolution of the
patient. RT limits natural evolution of the disease but has not been
shown to favor bone regeneration. The presence of osteoclasts in
the affected bones in active GSD justiﬁes the use of bispho-
sphonates. Intravenous bisphosphonates have been extensively
used in cancer patients with tumor bone disease and they are now
part of the routine management of patients with bone metastases
[23,26]. They markedly inhibit osteoclastic activity and decrease
the frequency of skeletal-related events. As judged by the suppres-
sion of CTX levels in our patient, osteoclast activity was markedly
inhibited and it is likely that zoledronic acid contributed to partial
bone regeneration [13,29] (Fig. 5). In parallel to the marked clinical
improvement, X-Rays and MRI suggested indeed new bone for-
mation. Such bone regeneration is extremely rare in GSD. A bone
biopsy after treatment would have probably conﬁrmed decreased
osteoclast activity and the progressive replacement of lymphagio-
matic and ﬁbrous tissue by a new bone formation but it was not
performed because it would not have inﬂuenced our therapeutic
attitude.
4. Conclusion
We report a well-documented case of Gorham–Stout disease in
the proximal aspect of ﬁbula invading proximal tibia and the
popliteal space. Clinical outcome was favorable after a conserva-
tive therapeutical approach including radiotherapy and bispho-
sphonates. Striking features of this report are the thorough
description on sequential MRIs, the histopathological aspect and
the close follow-up of bone metabolism during therapy.
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